Antibody-dependent natural killer cell activation after Ebola vaccination

Antibody-dependent natural killer cell activation after Ebola vaccination

<p><strong>Background</strong></p> <p>Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dep...

Full description

Bibliographic Details
Main Authors:	Wagstaffe, HR, Clutterbuck, EA, Bockstal, V, Stoop, JN, Luhn, K, Douoguih, M, Shukarev, G, Snape, MD, Pollard, AJ, Riley, EM, Goodier, MR
Format:	Journal article
Language:	English
Published:	Oxford University Press 2019

Similar Items

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
by: Wagstaffe, HR, et al.
Published: (2020)

Durable natural killer cell responses after heterologous two-dose Ebola vaccination
by: Helen R. Wagstaffe, et al.
Published: (2021-01-01)

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
by: Helen R. Wagstaffe, et al.
Published: (2022-05-01)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
by: Winslow, R, et al.
Published: (2017)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
by: Georgi Shukarev, et al.
Published: (2017-02-01)

IL-15 promotes polyfunctional NK cell responses to influenza by boosting IL-12 production
by: Wagstaffe, HR, et al.
Published: (2018)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
by: Viki Bockstal, et al.
Published: (2021-12-01)

Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination
by: Richardson, E, et al.
Published: (2024)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
by: Viki Bockstal, et al.
Published: (2022-11-01)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
by: Milligan, I, et al.
Published: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
by: Milligan, I, et al.
Published: (2016)

Persistence of immune responses induced by Ebola virus vaccines.
by: Snape, M
Published: (2017)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
by: Ramon Roozendaal, et al.
Published: (2020-12-01)

Ebola vaccination
by: Fitzgerald, F, et al.
Published: (2015)

Persistence of immune responses induced by Ebola virus vaccines
by: Matthew D Snape
Published: (2017-03-01)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
by: Marie Alexandre, et al.
Published: (2023-11-01)

Ebola: Profile of a Killer Virus
by: Stephen S. Morse
Published: (2017-11-01)

Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults
by: Macaya Douoguih, et al.
Published: (2016-05-01)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
by: Barry, H, et al.
Published: (2021)

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN®-Filo Ebola vaccine regimen: a phase 2 randomised clinical study in Europe (EBOVAC2)
by: Pollard, AJ, et al.
Published: (2020)

Long-term clinical safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: a prospective, multi-country, observational study
by: Puri, A, et al.
Published: (2024)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
by: Houreratou Barry, et al.
Published: (2021-10-01)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
by: Houreratou Barry, et al.
Published: (2021-10-01)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
by: Zacchaeus Anywaine, et al.
Published: (2022-01-01)

The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells
by: Avishay Edri, et al.
Published: (2018-07-01)

Detection of vaccine-induced antibodies to Ebola virus in oral fluid
by: Lambe, T, et al.
Published: (2016)

Human Antibody Repertoire following Ebola Virus Infection and Vaccination
by: Sandra Fuentes, et al.
Published: (2020-03-01)

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial
by: Neil Goldstein, et al.
Published: (2024-12-01)

Vaccines for Ebola
by: Editorial Article
Published: (2015-02-01)

Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies
by: Supriya Ravichandran, et al.
Published: (2022-08-01)

Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis.
by: Ravi Potluri, et al.
Published: (2020-01-01)

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study
by: Adeep Puri, et al.
Published: (2024-02-01)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
by: Viki Bockstal, et al.
Published: (2022-01-01)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
by: Viki Bockstal, et al.
Published: (2022-01-01)

Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo
by: Fabiola Blengio, et al.
Published: (2023-09-01)

Regulatory T cell profiles in patients with N-methyl-ᴅ-aspartate receptor-antibody encephalitis
by: Iro, MA, et al.
Published: (2023)

Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans
by: Rijal, P, et al.
Published: (2019)

Ebola virus shed glycoprotein is toxic to human T, B, and natural killer lymphocytes
by: Luis J. Perez-Valencia, et al.
Published: (2023-08-01)

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
by: Chelsea McLean, et al.
Published: (2023-09-01)

Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors
by: Pengfei Fan, et al.
Published: (2020-01-01)